Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CAPTN-3
    •     IM1240
    •     IM1305
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Author: Steven Epstein

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CAPTN-3
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech to Present IM1240 in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 at 15:00 CET in Barcelona, Spain.
  • Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.
  • Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
  • Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
  • CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
  • Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
  • CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
  • Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
  • APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
  • NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.

Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.

By afri-can
in
Events
Apr 18, 2023
Read more
Purple Biotech Presents NT219 Pre-Clinical Data at the  AACR 2023 Annual Meeting.

Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.

By afri-can
in
Events
Apr 16, 2023
Read more
Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.

Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.

By afri-can
in
News
Mar 27, 2023

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies

Read more
Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.

Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.

By afri-can
in
Events
Mar 20, 2023

March 20 2023 at 8:00 am – March 22 at 5:00 pm – UTC+0

Read more
Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.

Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.

By afri-can
in
News
Mar 14, 2023

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies

Read more
Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.

Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.

By afri-can
in
Events
Feb 01, 2023

February 6 2023 at 8:00 am – February 7 at 5:00 pm – UTC+0

Read more
Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023

Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023

By afri-can
in
Events
Dec 11, 2022

January 9 2023 at 8:00 am – January 12 at 5:00 pm – UTC+0

Read more
Purple Biotech to participate and Present at the Jefferies London Healthcare Conference

Purple Biotech to participate and Present at the Jefferies London Healthcare Conference

By afri-can
in
Events
Nov 11, 2022

November 15 2022 at 8:00 am – November 17 at 5:00 pm – UTC+0

Read more
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis 

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis 

By afri-can
in
Events
Nov 08, 2022

November 14 2022 at 8:00 am – November 17 at 5:00 pm – UTC+0

Read more
Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay

Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay

By afri-can
in
Events
Nov 01, 2022

November 8 2022 at 8:00 am – 5:00 pm – UTC+0

Read more
1 2 Next »
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2026 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset
We utilize cookies to improve our site and your experience when using it. To find more details, and to know how we obtain, store, and work with your personal data, check our Privacy Policy page.
You can revoke your consent any time using the Revoke consent button.